Investigation of antiischemic properties and mechanism of action of azacrown ether derivative.
The influence of the azacrown ether derivative benzylaza-15-crown-5 on myocardial tolerance to ischemia and on the functional state of the zone of myocardial ischemia during coronary artery occlusion was investigated in experiments on anaesthetized open-chest cats. The compound tested produced a dose-dependent antiischemic effect and prevented the development of myocardial ischemia. In experiments on isolated guinea-pig papillary muscle benzylaza-15-crown-5 inhibited the first and second components of the isoproterenol-induced muscle contraction. The compound decreased the maximal contraction force and had no effect on the cardiac cycle duration and on the time necessary for reaching maximal tension. It is suggested that the protective effect of benzylaza-15-crown-5 during myocardial ischemia is mediated through the inhibition of calcium release from the sarcoplasmic reticulum.
Gurbanov
K G
KG
Department of Pharmacology, Medical Institute, Volgograd, Russia.
Paperno
A A
AA
Bogomaz
S A
SA
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D043844:Crown Ethers; D004562:Electrocardiography / Q000187:drug effects; D004988:Ethers, Cyclic / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000517:prevention & control*; D010210:Papillary Muscles / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D043844:Crown Ethers; D004988:Ethers, Cyclic; C058863:benzylaza-15-crown-5; D007545:Isoproterenol